In a pooled secondary analysis of the phase 3 MAIA and ALCYONE trials in transplant-ineligible newly diagnosed myeloma, adding daratumumab raised grade 3/4 (36.9% vs 22.4%) and grade 5 (3.0% vs 1.5%) infections, but exposure-adjusted rates were generally comparable.
Secondary analysis
Bahlis et al. Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE